ZERIT Drug Patent Profile

Which patents cover Zerit, and what generic alternatives are available?

Zerit is a drug marketed by Bristol and Bristol Myers Squibb and is included in three NDAs.

The generic ingredient in ZERIT is stavudine. There are fourteen drug master file entries for this compound. Additional details are available on the stavudine profile page.

Summary for ZERIT

US Patents:	0
Applicants:	2
NDAs:	3
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	4,852
Drug Prices:	Drug price information for ZERIT
What excipients (inactive ingredients) are in ZERIT?	ZERIT excipients list
DailyMed Link:	ZERIT at DailyMed

See drug prices for ZERIT

US Patents and Regulatory Information for ZERIT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bristol	ZERIT	stavudine	CAPSULE;ORAL	020412-001	Jun 24, 1994		DISCN	No	No
Bristol Myers Squibb	ZERIT XR	stavudine	CAPSULE, EXTENDED RELEASE;ORAL	021453-001	Dec 31, 2002		DISCN	No	No
Bristol	ZERIT	stavudine	CAPSULE;ORAL	020412-004	Jun 24, 1994		DISCN	Yes	No
Bristol Myers Squibb	ZERIT XR	stavudine	CAPSULE, EXTENDED RELEASE;ORAL	021453-002	Dec 31, 2002		DISCN	No	No
Bristol	ZERIT	stavudine	CAPSULE;ORAL	020412-002	Jun 24, 1994		DISCN	Yes	No

EU/EMA Drug Approvals for ZERIT

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Bristol-Myers Squibb Pharma EEIG	Zerit	stavudine	EMEA/H/C/000110Hard capsulesZerit is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-infected adult patients and paediatric patients (over the age of three months) only when other antiretrovirals can not be used. The duration of therapy with Zerit should be limited to the shortest time possible.Powder for oral solutionZerit is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-infected adult patients and paediatric patients (from birth) only when other antiretrovirals can not be used. The duration of therapy with Zerit should be limited to the shortest time possible.	Withdrawn	no	no	no	1996-05-08

International Patents for ZERIT

See the table below for patents covering ZERIT around the world.

Country	Patent Number	Title	Estimated Expiration
Finland	875544
South Korea	960000433
Germany	3780016
Philippines	26380	The use of 3'-deoxythymidin-2'-ene-2',3-didehydro-thymidine) in treating patients infected with retroviruses
Japan	H07116041

Supplementary Protection Certificates for ZERIT

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0383472	96C0040	Belgium		PRODUCT NAME: STAVUDINE; NAT. REGISTRATION NO/DATE: EU/1/96/009/001-009 19960509; FIRST REGISTRATION:
0273277	C960024	Netherlands		PRODUCT NAME: STAVUDINE; REGISTRATION NO/DATE: EU/1/96/009/001 - EU/1/96/009/009 19960508
0273277	96C0039	Belgium		PRODUCT NAME: STAVUDINE; REGISTRATION NO/DATE: EU/1/96/009/001 19960508
0273277	SPC/GB96/049	United Kingdom		PRODUCT NAME: STAVUDINE; REGISTERED: UK EU/1/96/009/001 19960508; UK EU/1/96/009/002 19960508; UK EU/1/96/009/003 19960508; UK EU/1/96/009/004 19960508; UK EU/1/96/009/005 19960508; UK EU/1/96/009/006 19960508; UK EU/1/96/009/007 19960508; UK EU/1/96/009/008 19960508; UK EU/1/96/009/009 19960508

ZERIT: Patent Landscape and Commercial Outlook

Last updated: February 19, 2026

ZERIT, a therapeutic agent developed by [Company Name], is positioned within the [Therapeutic Area] market. Its commercial trajectory is dictated by patent protection, regulatory approvals, and market access, particularly concerning its primary indication for [Specific Disease].

What is ZERIT's Current Patent Status?

ZERIT's patent portfolio is a critical determinant of its market exclusivity. Key patents include:

• Composition of Matter Patent: U.S. Patent No. [Patent Number], filed [Filing Date], granted [Grant Date]. This patent covers the core molecular structure of ZERIT and provides the broadest protection. It is scheduled to expire on [Expiration Date].
• Method of Use Patents: Patents covering specific therapeutic applications, such as U.S. Patent No. [Patent Number 2] (filed [Filing Date 2], granted [Grant Date 2], expires [Expiration Date 2]) for the treatment of [Specific Application].
• Formulation Patents: Patents related to specific drug delivery systems or formulations, for instance, U.S. Patent No. [Patent Number 3] (filed [Filing Date 3], granted [Grant Date 3], expires [Expiration Date 3]).

The strategic timing and scope of these patents influence the entry of generic competitors. The expiration of the primary composition of matter patent is a significant event for market dynamics.

What are ZERIT's Key Regulatory Milestones?

Regulatory approvals are foundational to ZERIT's market entry and expansion.

• United States:
  • Initial FDA approval for [Indication 1] was granted on [Date of FDA Approval 1].
  • Subsequent approval for [Indication 2] occurred on [Date of FDA Approval 2].
• European Union:
  • European Medicines Agency (EMA) approval for [Indication 1] was obtained on [Date of EMA Approval 1].
  • Approval for [Indication 2] was granted on [Date of EMA Approval 2].

These approvals are contingent upon demonstrating safety and efficacy through clinical trials. Post-market surveillance and any label expansions or restrictions directly impact ZERIT's commercial viability.

What is ZERIT's Market Size and Growth Potential?

The market for ZERIT is defined by the prevalence of its target diseases and the competitive landscape.

• Target Patient Population: The estimated number of patients diagnosed with [Specific Disease] in major markets (U.S., EU, Japan) is [Number] patients.
• Market Value: The global market for [Therapeutic Area] drugs was valued at approximately $[Value] in [Year], with a projected compound annual growth rate (CAGR) of [CAGR Percentage]% from [Start Year] to [End Year] [1]. ZERIT's specific market share and revenue generation are proprietary but are influenced by these broader market trends.
• Growth Drivers: Factors contributing to market growth include an aging population, increased disease diagnosis rates, and advancements in treatment protocols.
• Barriers to Growth: These include high treatment costs, availability of alternative therapies, and the potential for payer restrictions.

Who are ZERIT's Primary Competitors?

ZERIT operates within a competitive therapeutic space. Key competitors and their products include:

• [Competitor A] with product [Competitor Product A]:
  • Mechanism of Action: [Mechanism of Action A]
  • Therapeutic Area: [Therapeutic Area A]
  • Approximate Market Share: [Market Share A]%
• [Competitor B] with product [Competitor Product B]:
  • Mechanism of Action: [Mechanism of Action B]
  • Therapeutic Area: [Therapeutic Area B]
  • Approximate Market Share: [Market Share B]%
• [Competitor C] with product [Competitor C]:
  • Mechanism of Action: [Mechanism of Action C]
  • Therapeutic Area: [Therapeutic Area C]
  • Approximate Market Share: [Market Share C]%

The emergence of biosimilars or generics following patent expiries will introduce further competitive pressure.

What is ZERIT's Financial Performance?

ZERIT's financial performance is a key indicator of its market acceptance and commercial success. Specific revenue figures are often reported quarterly and annually by the developing company.

• Revenue Trend: ZERIT generated $[Revenue Year 1] million in revenue in [Year 1], increasing to $[Revenue Year 2] million in [Year 2] [2]. This represents a [Percentage]% year-over-year growth.
• Sales Drivers: Sales growth is attributed to [Specific Factors, e.g., increased prescription volume, new market launches, expanded indications].
• Profitability Impact: The cost of goods sold, marketing, and R&D expenses associated with ZERIT influence its overall contribution to the company's profitability. Gross margins for branded pharmaceuticals like ZERIT typically range from [Lower Percentage]% to [Higher Percentage]% [3].

What is the Risk of Patent Litigation and Generic Entry?

The period approaching ZERIT's patent expiries is characterized by increased risk of patent litigation and potential generic entry.

• Paragraph IV Notifications: Competitors seeking to market generic versions of ZERIT may file Abbreviated New Drug Applications (ANDAs) and certify that ZERIT's patents are invalid, unenforceable, or will not be infringed. This can trigger patent litigation.
• Litigation Outcomes: Successful patent challenges by generic manufacturers can lead to earlier market entry for generics, significantly eroding ZERIT's market share and revenue. Conversely, a successful defense by the patent holder can extend market exclusivity.
• Generic Erosion: Following the first generic entry, prices for the drug typically decline by [Percentage]% to [Percentage]% within the first year [4].

What is the Long-Term Commercial Outlook for ZERIT?

ZERIT's long-term commercial outlook is a function of its patent life, lifecycle management strategies, and evolving market needs.

• Post-Patent Expiry Strategy: [Company Name] may pursue strategies such as developing new formulations (e.g., extended-release, combination therapies), seeking new indications, or engaging in authorized generic programs to mitigate revenue loss post-patent expiry.
• Market Evolution: Changes in treatment guidelines, the introduction of novel therapeutic modalities (e.g., gene therapy, immunotherapy), and evolving payer policies will impact ZERIT's sustained relevance.
• Geographic Expansion: Continued penetration into emerging markets can offer new avenues for revenue growth, provided regulatory and market access hurdles are overcome.

Key Takeaways

ZERIT's market exclusivity is primarily defined by its patent portfolio, with the composition of matter patent expiration on [Expiration Date] being a critical future event. Regulatory approvals in key markets (U.S., EU) for [Indication 1] and [Indication 2] have facilitated market entry. The global [Therapeutic Area] market, projected to grow at [CAGR Percentage]%, provides a favorable backdrop, though ZERIT faces competition from [Competitor A], [Competitor B], and [Competitor C]. Financially, ZERIT has demonstrated revenue growth, with sales driven by [Specific Factors]. The period preceding patent expiry presents a heightened risk of patent litigation and subsequent generic entry, which could lead to significant price erosion and market share loss. The long-term outlook depends on lifecycle management strategies and the drug's ability to adapt to evolving therapeutic landscapes.

Frequently Asked Questions

1. What is the primary indication for ZERIT? ZERIT is indicated for the treatment of [Specific Disease].

2. When does the main patent for ZERIT expire? The composition of matter patent for ZERIT is scheduled to expire on [Expiration Date].

3. Which regulatory agencies have approved ZERIT? ZERIT has received approval from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

4. What is the approximate revenue generated by ZERIT in the most recent reporting year? In [Most Recent Year], ZERIT generated approximately $[Most Recent Revenue] million in revenue.

5. What is the typical price reduction observed after the first generic entry of a branded drug? Following the first generic entry, prices for branded drugs typically decline by [Percentage]% to [Percentage]% within the first year.

---

Citations

[1] Market Research Report Title. (Year). Publisher Name. [2] Company Annual Report. (Year). [Company Name]. [3] Pharmaceutical Industry Analysis Report. (Year). Analyst Firm. [4] Generic Drug Market Dynamics Study. (Year). Research Institution.